Sanofi (EPA:SANNV)
France · Delayed Price · Currency is EUR | Market Cap | 90.99B -9.2% |
| Revenue (ttm) | 47.35B +4.8% |
| Net Income | 7.56B +19.9% |
| EPS | 6.20 +23.0% |
| Shares Out | n/a |
| PE Ratio | 12.04 |
| Forward PE | 8.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,602 |
| Open | 106.28 |
| Previous Close | 105.20 |
| Day's Range | 103.42 - 106.50 |
| 52-Week Range | 93.74 - 106.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com...
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive d...
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, ...
Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopen...
MacroGenics to receive $24.5M milestone payment from Sanofi
MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration’s accelerated approval of TZIELD to delay the ...
Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi (SNY) announced the appointment of Paulo Fontoura, MD, PhD, FAAN, as Executive Vice President, Global Head of Research & Development Pharma, effective September 1. “He will be a member…
Sanofi investors likely to view new R&D head as a positive, says BofA
After Sanofi (SNY) announced a new head of R&D with Paulo Fontoura replacing Houman Ashrafian, BofA analyst Sachin Jain says investors are likely to view Fontoura’s appointment as a positive…
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026. Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, G...
Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-i...
Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sanofi (SNY) to EUR 95 from EUR 100 and keeps a Buy rating on the shares.
Sanofi: Information concerning the total number of voting rights and shares – May 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
The U.S. Food and Drug Administration approved Sanofi's injection to slow the loss of the body's own insulin production in children aged 8 to 17 years recently diagnosed with stage 3 typ...
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move ...
Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright
After Sanofi (SNY) announced that it is stopping the pivotal MOBILIZE study evaluating riliprubart in chronic inflammatory demyelinating polyneuropathy patients refractory to standard of care based on...
Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
Stifel notes that Sanofi (SNY) announced this morning that they are discontinuing the MOBILIZE Phase 3 study of riliprubart in CIDP patients refractory to IVIg based on an IDMC interim…
Dianthus sinks after Sanofi halts CIDP Phase 3 study
Shares of Dianthus Therapeutics (DNTH) after sinking after Sanofi (SNY) announced that its riliprubart Phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy will be stopped....
Sanofi to halt riliprubart Mobilize phase 3 study
Sanofi (SNY) announced that the riliprubart Mobilize phase 3 study in patients with chronic inflammatory demyelinating polyneuropathy, CIDP, refractory to standard-of-care treatment will be stopped. T...
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient...
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 . Sanofi today announced that the riliprubart MOBILIZE phase ...
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaborat...
Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.